secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-08-14T12:36:29+00:00
Accession:  0001104659-26-096510
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics raises ~$55M in public offering of common stock and warrants
--------------------------------------------------------------------------------

- 55,555,556 shares and warrants sold at $0.99 combined; gross proceeds ~$55M.
- Warrants exercisable at $1.10/share, expire in 5 years; underwriters' option for 8.33M additional warrants exercised.
- GMS Ventures (largest stockholder) bought 2,525,252 shares; CEO Robert Jahr and CFO Lawrence Kenyon bought 151,515 and 101,010 shares respectively.
- Offering expected to close Aug 14, 2026; Piper Sandler and BTIG are underwriters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926096510/0001104659-26-096510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926096510/tm2622399d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-096510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer